z-logo
open-access-imgOpen Access
Combination of Laser-Therapy with 0.5% Idoxuridine Cream in the Treatment of Therapy-Resistant Genital Warts in Male Patients
Author(s) -
Hannu-Pekka Happonen,
A Lassus,
J Santalahti,
S. Forsström,
Jan Lassus
Publication year - 1990
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/00007435-199007000-00003
Subject(s) - medicine , idoxuridine , laser therapy , dermatology , genital warts , condyloma acuminatum , human papillomavirus , virology , laser , virus , syphilis , physics , optics , human immunodeficiency virus (hiv)
Forty heterosexual male patients with therapy resistant penile warts of long duration (mean 12.9 months) were treated with carbon dioxide laser, immediately followed by topical application of 0.5% idoxuridine cream twice daily for 14 days. In case of incomplete or no response to the initial treatment, the treatment procedure was repeated once. All patients had previously been repeatedly treated with podophyllotoxin 0.5% solution and/or carbon dioxide laser surgery. After two weeks of treatment, 32 patients (80%) were completely healed. The remaining eight patients were retreated and four weeks after the start of the study 35 patients (87.5%) showed complete response. Three months after the study had been initiated 34 patients (85%) were still completely healed. No adverse reactions were observed. It was concluded that laser surgery followed by topical application of 0.5% idoxuridine cream for two to four weeks seems to be highly effective in the treatment of longstanding, therapy-resistant genital warts in men. Because of the uncontrolled nature of the present study and the relatively small number of patients treated, it would be important to carry out controlled studies in larger study populations and to carry out a follow-up examination of at least six months after treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here